Valion Bio advances Entolimod platform with government engagement, 200x manufacturing scale-up, oncology expansion

Valion Bio, Inc.

Continued discussions with BARDA, NIAID, AFRRI, and U.S. Department of War for ARS preparedness and stockpile opportunities.
Ukraine's Ministry of Health evaluating Entolimod for potential inclusion in national strategic reserves; no agreement yet.
Demonstrated 200-fold manufacturing scale-up via Velocity Bioworks, producing ~1.3M potential human doses at 50L fermentation scale.
Planning physician-sponsored studies of Entolimod in neutropenia; advancing next-gen TLR5 agonist Entolasta for oncology supportive care.
Over $140M invested in Entolimod development to date; company building integrated platform across biodefense, manufacturing, and oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.